



2Q 2026 Financial Results

August 4, 2026



Overview

On May 26, 2026, DuPont's Board of Directors announced a reverse stock split of the Company's common stock, par value \$0.01 per share, at a ratio of 1-for-3, as well as a reduction in the number of authorized shares of its common stock by a corresponding ratio (the "Reverse Stock Split"), as approved by shareholders. The Reverse Stock Split became effective on June 24, 2026. All share and share-related information presented in these interim Consolidated Financial Statements has been retroactively adjusted in all periods presented to reflect the decreased number of shares resulting from the Reverse Stock Split and related impacts.

On April 1, 2026, DuPont completed the sale of the Aramids business (the "Aramids Business" and the divestiture of the Aramids Business, the "Aramids Divestiture") to Arclin, a portfolio company of an affiliate of TJC LP for pre-tax cash proceeds of approximately \$1.2 billion, subject to customary transaction adjustments, a note receivable in the principal amount of \$300 million (the "Aramids Note Receivable") and a non-controlling common equity interest (the "Aramids Equity Consideration"), valued at \$325 million, in New Arclin U.S. Holding Corp., which now owns the Arclin global materials business and the Aramids Business. The financial results of the divested Aramids Business are reflected in DuPont's interim Consolidated Financial Statements as discontinued operations, along with comparative periods.

On November 1, 2025, DuPont completed the separation of its semiconductor and interconnect solutions businesses (the "Electronics Business" and the separation of the Electronics Business, the "Electronics Separation") into an independent public company, Qnity Electronics, Inc. ("Qnity"), by way of the distribution to DuPont's stockholders of record as of October 22, 2025 of all the issued and outstanding common stock of Qnity on November 1, 2025 (the "Qnity Distribution"). As a result, the financial results of the divested Electronics Business are reflected in DuPont's interim Consolidated Financial Statements as discontinued operations for all periods.

Cautionary Statement Regarding Forward-looking Statements

Certain statements in this release may be considered forward-looking statements, within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Forward-looking statements often contain words such as "expect", "anticipate", "intend", "plan", "believe", "seek", "see", "will", "would", "target", "outlook", "stabilization", "confident", "preliminary", "initial", "continue", "may", "could", "project", "estimate", "forecast" and similar expressions and variations or negatives of these words. All statements, other than statements of historical fact, are forward-looking statements. Forward-looking statements address matters that are, to varying degrees, uncertain and subject to risks, uncertainties, and assumptions, many of which are beyond DuPont's control, that could cause actual results to differ materially from those expressed in any forward-looking statements.

Forward-looking statements are not guarantees of future results. Some of the important factors that could cause DuPont's actual results to differ materially from those projected in any such forward-looking statements include, but are not limited to (i) the ability to realize the intended benefits of the Electronics Separation and the Qnity Distribution, including achievement of the intended tax treatment, contractual allocation to, and assumption by Qnity of certain liabilities, including certain legacy liabilities with respect to per- and polyfluoroalkyl substances ("PFAS") and the possibility of disputes, litigation or unanticipated costs in connection with the Electronics Separation and Qnity Distribution; (ii) the impact of the Aramids Divestiture on DuPont's balance sheet, financial condition and future results of operations; (iii) risks and costs related to the impact of the arrangement to share future eligible PFAS costs by and among DuPont, Corteva, Inc. and The Chemours Company, including the outcome of pending or future litigation related to PFAS or PFOA, which includes personal injury claims and natural resource damages claims; the extent and cost of ongoing and potential future remediation obligations; and changes in laws and regulations applicable to PFAS chemicals; (iv) the failure to realize expected benefits and effectively manage and achieve anticipated synergies and operational efficiencies in connection with the Electronics Separation, the Aramids Divestiture and completed and future, if any, divestitures, mergers, acquisitions, and other portfolio management, productivity and infrastructure actions; (v) risks and uncertainties that are outside the Company's control but adversely impact the overall environment in which DuPont, its customers and/or its suppliers operate, including changes in economic, political, regulatory, international trade, geopolitical, military conflicts, capital markets and other external conditions, including pandemics and responsive actions, as well as natural and other disasters or weather-related events; (vi) the ability to offset increases in cost of inputs, including raw materials, energy and logistics; (vii) the risks and uncertainties associated with continuing or expanding geopolitical conflicts or trade disputes or restrictions and responsive actions, new or increased tariffs or export controls, including on exports to China of U.S.-regulated products and technology; (viii) other risks to DuPont's business and operations, including the risk of impairment; (ix) risks and uncertainties in connection with completing the \$2 billion share buyback announced on November 6, 2025, including timeline, associated costs and the possibility that the authorization may be suspended or discontinued prior to completion; (x) the ability to realize the intended benefits of the Reverse Stock Split; (xi) the impact of the invalidation of certain tariffs imposed under the International Emergency Economic Powers Act and (xii) other risk factors discussed in DuPont's most recent annual report on Form 10-K, and subsequent quarterly reports on Form 10-Q and current reports on Form 8-K filed with the U.S. Securities and Exchange Commission.

Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business or supply chain disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on DuPont's consolidated financial condition, results of operations, credit rating or liquidity. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. DuPont assumes no obligation to publicly provide revisions or updates to any forward-looking statements whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.

Non-GAAP Financial Information

This presentation includes information that does not conform to accounting principles generally accepted in the United States of America ("U.S. GAAP") and are considered non-GAAP measures. Refer to slide 13 for descriptions of these non-GAAP measures such as Operating EBTIDA, Operating EBITDA Margin, Adjusted EPS, Transaction-adjusted free cash flow and related conversion, Pro Forma Operating EBITDA, Pro Forma Operating EBITDA Margin, Pro Forma Adjusted EPS, and various other measures that adjust for the impacts of significant items. These non-GAAP financial measures supplement disclosures prepared in accordance with U.S. GAAP and should not be viewed as an alternative to GAAP measures of performance. Furthermore, these non-GAAP measures may not be consistent with similar measures provided by other companies. Reconciliations of our non-GAAP measures included within this presentation are included in the "Non-GAAP Financial Measures" section of this presentation.



Strong Execution Driving Results

2Q 2026 Financials

- ✓ **+4%** organic sales growth led by healthcare and aerospace end-markets
- ✓ **+80 bps** margin expansion¹ driven by productivity and operating leverage
- ✓ **+21%** EPS growth¹ reflecting disciplined execution
- ✓ **+127%** free cash flow conversion on working capital discipline
- ✓ **Raises** full year financial guidance
- ✓ Announces **\$250 million** share repurchase

Operational Highlights

- ✓ Continued advancement of strategic priorities – organic growth, business system progression, productivity, and capital deployment
- ✓ Completed the 1-for-3 reverse stock split
- ✓ GICS Code classification changed to Industrials effective July 31st

Continued Execution on Strategic Priorities



Robust Business System Driving Growth & Continuous Improvement

- ✓ Continued focus on accountability, productivity and performance excellence
- ✓ Reinforced operating culture to drive execution and sustainable performance



Innovation

- ✓ Key product launches in high growth verticals
 - Direct lithium extraction in Water
 - Liveo™ assemblies for biopharma
- ✓ Advancing digital and AI capabilities to accelerate cycle times



Commercial

- ✓ Continued improvement in overall order trends
- ✓ Scaling demand generation through AI
 - ~50 sales plays launched
 - ~150 opportunities won
 - ~30% win rate



Operational

- ✓ Expanded continuous improvement initiatives across businesses and sites, driving productivity gains
 - >100 bps net productivity
 - > 50 bps COPQ¹
 - > 100 bps OTIF²

- ✓ Held annual CEO kaizen; 22 events across both businesses and functions
- ✓ Completed 80/20 pilot work to enhance growth, strengthen channel partnerships, and reduce manufacturing complexities

2Q 2026 Financial Highlights

Sales Drivers

Net Sales
\$1.8 billion
+4% YoY

Organic Sales
+4%

Organic Sales:

Broad-based end-market growth, led by healthcare and aerospace

Currency: flat
Portfolio: flat

Organic Sales by Segment:

Healthcare & Water Technologies: +4%
Diversified Industrials: +3%

Profitability & Cash Flow


Operating EBITDA
\$448 million

Adjusted EPS
\$1.88/share

Transaction-Adjusted FCF¹
\$326 million


- Up 6% year-over-year on organic growth and productivity; +8% versus prior year pro forma
- Margin +40 bps to 24.6%; +80 bps versus prior year pro forma
- Higher segment earnings and lower net interest expense and tax rate
- +48% YoY; +21% versus prior year pro forma
- +127% conversion

2Q 2026 Adjusted EPS Bridge



2Q 2026 Segment Results


Healthcare & Water Technologies



End-market highlights

- **Healthcare Technologies Organic Growth +MSD**
 - Double-digit growth in personal protection and biopharma markets
- **Water Technologies Organic Growth +LSD**
 - Double-digit growth in industrial water and semiconductor markets
 - Offset by weakness in the Middle East region

Diversified Industrials



End-market highlights

- **Building Technologies Organic Growth +LSD**
 - Growth in residential and non-residential construction
- **Industrial Technologies Organic Growth +MSD**
 - Double-digit growth in aerospace and electric vehicle battery applications
 - Mid-single digit growth in printing applications

2026 Guidance

FY2026 Guidance (Dollars in millions, except EPS)

	Prior Guidance	Current Guidance	Mid-point Changes
Net Sales	\$7,155 - \$7,215	\$7,160 - \$7,190	-\$10 (+\$20 excluding currency headwinds)
Operating EBITDA	\$1,730 - \$1,760	\$1,750 - \$1,770	+\$15
Adjusted EPS	\$7.02 - \$7.16	\$7.17 - \$7.32	+\$0.15

2H2026 Guidance (Dollars in millions, except EPS)

	2H 2026
Net Sales	\$3,660 - \$3,690
Operating EBITDA	\$890 - \$910
Adjusted EPS	\$3.65 - \$3.80

Key Assumptions


Organic sales growth now slightly **above 4 percent** YoY

FY'26 Operating EBITDA and Adjusted EPS **mid-point raised** on stronger underlying results more than offsetting currency headwinds
FY Adjusted EPS growth of **17-19 percent** versus prior year pro forma

2H'26 Net Sales assumes ~**6 percent organic sales growth** YoY


Appendix

2Q 2026 Net Sales Bridge



2026 Segment Expectations

Healthcare & Water Technologies



2H2026

- Expect high-single digit organic sales growth year-over-year
- Strength in medical packaging, personal protection and industrial water is more than offsetting headwinds in the Middle East

FY2026

- Expect mid-single digit organic sales growth year-over-year; broad-based strength in Healthcare driven by medical packaging and medical devices; Growth in Water led by strength in industrial and semiconductor markets

Diversified Industrials



2H2026

- Expect mid-single digit organic sales growth year-over-year
- Growth in aerospace and industrial end-markets; includes year-over-year growth in construction end-markets

FY2026

- Expect low-single digit organic sales growth year-over-year; Industrial Technologies growth driven by strength in aerospace and demand recovery in industrial markets; Building Technologies up slightly

Additional Modeling Guidance

Additional Modeling Guidance

Base Tax Rate	~24.5% - FY 26
D&A	~\$625 million, pre-tax
Depreciation	~\$350 million, pre-tax
Intangible Amortization	~\$275 million, pre-tax
Interest Expense, net	~\$75 million, pre-tax
Exchange Losses	~\$5-\$10 million, after-tax
Share count – diluted ¹	~135 million – 2H 26
Weighted Average	~136 million – FY 26
Corporate	~\$115 million – FY 26

Non-GAAP Financial Measures:

Unless otherwise indicated, all financial metrics presented reflect continuing operations only.

This communication includes information that does not conform to accounting principles generally accepted in the United States of America (“U.S. GAAP”) and are considered non-GAAP measures. Management uses these measures internally for planning, forecasting and evaluating the performance of the Company, including allocating resources. DuPont’s management believes these non-GAAP financial measures are useful to investors because they provide additional information related to the ongoing performance of DuPont to offer a more meaningful comparison related to future results of operations. These non-GAAP financial measures supplement disclosures prepared in accordance with U.S. GAAP, and should not be viewed as an alternative to U.S. GAAP. Furthermore, such non-GAAP measures may not be consistent with similar measures provided or used by other companies. Reconciliations for these Non-GAAP measures to U.S. GAAP are provided in the Selected Financial Information and Non-GAAP Measures starting on page 16. Non-GAAP measures included in this communication are defined below. The Company has not provided forward-looking U.S. GAAP financial measures or a reconciliation of forward-looking non-GAAP financial measures to the most comparable U.S. GAAP financial measures on a forward-looking basis because the Company is unable to predict with reasonable certainty the ultimate outcome of certain future events. These events include, among others, the impact of portfolio changes, including asset sales, mergers, acquisitions, and divestitures; contingent liabilities related to litigation, environmental and indemnifications matters; impairments and discrete tax items. These items are uncertain, depend on various factors, and could have a material impact on U.S. GAAP results for the guidance period.

Key Terms

Significant Items

Significant items are items that arise outside the ordinary course of business for the Company and includes items for nonconsolidated affiliates, that the Company’s management believes may cause misinterpretation of underlying business and investment performance, both historical and future, based on a combination of some or all of the item’s size, unusual nature and infrequent occurrence. Management classifies as significant items certain costs and expenses associated with integration and separation activities related to transformational acquisitions and divestitures as they are considered unrelated to ongoing business performance. There were no significant items associated with nonconsolidated affiliates recorded for the three and six month periods ended June 30, 2026 and June 30, 2025.

Future Reimbursable Indirect Costs

Indirect costs, such as those related to corporate and shared service functions previously allocated to the separated Electronics Business and Aramids Business, do not meet the criteria for discontinued operations and are reported within continuing operations in all respective periods presented. The Company has, is, will or expects to be reimbursed in accordance with the applicable transition service agreements (“TSAs”) for the portion of indirect costs related to activities the Company is, will or expects to undertake on a transitional basis to support a) Qnity not beyond year end 2027 for services and 2040 for site leases and, b) the Aramids Business post the Aramids Divestiture, but not beyond 2028 (such indirect costs “Future Reimbursable Indirect Costs”). Services provided and costs reimbursed in accordance with the applicable TSAs include but are not limited to, costs associated with information technology services/support, product stewardship and regulatory support, facilities services, and shared property lease costs.

Future Reimbursable Indirect Costs do not meet the criteria for discontinued operations and therefore are included in both GAAP Net Income from Continuing Operations and in GAAP Cash provided by operating activities-continuing operations for all periods presented. Future Reimbursable Indirect Costs are excluded from Adjusted Earnings, Operating EBITDA and Transaction-Adjusted Free Cash Flow, each defined below. Such indirect costs that are not subject to future reimbursement are reported within continuing operations in Corporate and are included within Adjusted Earnings, Operating EBITDA, and Cash provided by operating activities-continuing operations.

Corporate DDOB Remediation Costs

Corporate DDOB Remediation Costs are environmental remediation costs, including certain investigate, remediate and restoration costs, associated with discontinued or divested operations, businesses or product lines (“Corporate DDOB Remediation Costs”). DDOB Remediation Costs are excluded from Adjusted Earnings and Operating EBITDA, as defined below, to provide better insight into the underlying business performance of the Company.



Non-GAAP Financial Measures Definitions

Organic Sales

Organic Sales is defined as net sales excluding the impacts of currency and portfolio.

Adjusted Earnings

Adjusted Earnings is defined as income from continuing operations excluding the after-tax impact of significant items, after-tax impact of amortization expense of intangibles, the after-tax impact of non-operating pension / other post employment benefits ("OPEB") credits / costs, Future Reimbursable Indirect Costs and Corporate DDOB Remediation Costs.

Adjusted Earnings is the numerator used in the calculation of Adjusted EPS, as well as the denominator in Adjusted Free Cash Flow Conversion.

Adjusted EPS

Adjusted EPS is defined as Adjusted Earnings per common share - diluted. Management estimates amortization expense in 2026 associated with intangibles to be about \$275 million on a pre-tax basis, or approximately \$1.54 per share.

Operating EBITDA, EBITDA Margin & Incremental Margin

The Company's measure of profit/loss for segment reporting purposes is Operating EBITDA as this is the manner in which the Company's chief operating decision maker ("CODM") assesses performance and allocates resources. The Company defines Operating EBITDA as earnings (i.e., "Income from continuing operations before income taxes") before interest, depreciation, amortization, non-operating pension / OPEB benefits / charges, and foreign exchange gains / losses, excluding Future Reimbursable Indirect Costs, Corporate DDOB Remediation Costs, and adjusted for significant items. Reconciliations of these measures are provided on the following pages.

Operating EBITDA Margin is defined as Operating EBITDA divided by Net Sales.

Incremental Margin is the change in Operating EBITDA divided by the change in Net Sales for the applicable period.

Pro Forma Operating EBITDA, Pro Forma Operating Margin, and Pro Forma Adjusted EPS

Management uses the supplemental pro forma non-GAAP financial measures to assist in evaluating DuPont's results as a stand-alone company for the twelve months ended December 31, 2025 following the November 1, 2025 separation of Qnity. These measures are intended to reflect the impact of the separation on the Company's historical non-GAAP results by adjusting for corporate cost and capital structure changes that occurred as a result of the separation. Management believes these measures provide a more meaningful comparison of the Company's historical non-GAAP results in relation to future results of operations. The 2025 pro forma amounts are adjusted as if the separation occurred on January 1, 2025 for comparability. The Corporate cost benefit reflects the elimination of costs associated with the separation of Qnity that are not included in discontinued operations and relate primarily to corporate functions that no longer support the Company's continuing operations. These supplemental pro forma non-GAAP financial measures are not prepared in accordance with Article 11 of Regulation S-X and should not be viewed as an alternative to U.S. GAAP.

Pro Forma Operating EBITDA is defined as Operating EBITDA adjusting for the impact of the reduction in corporate costs post separation, inclusive of changes in Delrin equity earnings/losses.

Pro Forma Adjusted EPS is defined as Adjusted EPS adjusting for the impact of changes in net interest expense resulting from the post-separation capital structure, and the impact of the reduction in corporate costs post separation (inclusive of changes in Delrin equity earnings/losses) and applying a 25.5 percent adjusted base tax rate.



Non-GAAP Financial Measures Definitions (Continued)

Adjusted Free Cash Flow & Adjusted Free Cash Flow Conversion

Adjusted Free Cash Flow is defined as cash provided by/used for operating activities from continuing operations less capital expenditures and excluding the impact of cash inflows/outflows that are unusual in nature and/or infrequent in occurrence that neither relate to the ordinary course of the Company's business nor reflect the Company's underlying business liquidity. As a result, Adjusted Free Cash Flow represents cash that is available to the Company, after investing in its asset base, to fund obligations using the Company's primary source of liquidity, cash provided by operating activities from continuing operations. Management believes Adjusted Free Cash Flow, even though it may be defined differently from other companies, is useful to investors, analysts and others to evaluate the Company's cash flow and financial performance, and it is an integral measure used in the Company's financial planning process. Management notes that there were no exclusions for items that are unusual in nature and/or infrequent in occurrence for the three and six month periods ended June 30, 2026.

Adjusted Free Cash Flow Conversion is defined as Adjusted Free Cash Flow divided by Adjusted Earnings. Management uses Adjusted Free Cash Flow Conversion as an indicator of our ability to convert earnings to cash.

Transaction Adjusted Free Cash Flow & Transaction Adjusted Free Cash Flow Conversion

Management believes supplemental non-GAAP financial measures including Transaction-Adjusted Free Cash Flow and Transaction-Adjusted Free Cash Flow Conversion (each defined below) provide an integral view of information on the Company's underlying business performance during this period of transformational change. Management believes the Electronics Separation and Aramids Divestiture collectively represent a significant transformational change for the Company and separation-related transaction cost payments impact comparability to the Company's continuing operations. Management believes Transaction-Adjusted Free Cash Flow, which may be defined differently from other companies, is useful to investors, analysts and others to evaluate the Company's cash flow and financial performance, and it is an integral measure used in the Company's financial planning process. These non-GAAP financial measures are not intended to represent residual cash flow for discretionary expenditures since other non-discretionary expenditures, such as mandatory debt service requirements, are not deducted from the measure.

Transaction-Adjusted Free Cash Flow is defined as cash provided by/used for operating activities from continuing operations less capital expenditures and removing the impact of separation-related transaction costs and other payment and cash inflows/outflows that are unusual in nature and/or infrequent in occurrence that neither relate to the ordinary course of the Company's business nor reflect the Company's underlying business liquidity.

Transaction-Adjusted Free Cash Flow Conversion is defined as Transaction-Adjusted Free Cash Flow excluding separation-related transaction costs, divided by Adjusted Earnings.

Separation-related transaction costs and other payments include cash outflows directly associated with the Electronics Separation and the Aramids Divestiture. These costs include advisor and banking fees, payments related to establishing a new capital structure (including fees associated with interest rate swaps), capital expenditures required to facilitate physical asset separation, restructuring payments associated with senior leadership, and Future Reimbursable Indirect Costs, among other expenditures.

Future Reimbursable Indirect Costs are excluded from Adjusted Earnings and Operating EBITDA. To provide comparable data analysis, the Company has also adjusted payments associated with Future Reimbursable Indirect Costs within Separation-related transaction costs and other payments. This adjustment is intended to provide insight into the Company's underlying business performance. For the six months ended June 30, 2026, the Company adjusted \$8 million associated with Future Reimbursable Indirect Costs within Separation-related transaction costs and other payments.

Additionally, \$2 and \$5 million were reflected in Separation-related transaction costs and other payments for the three and six month periods ended June 30, 2026, respectively, for capital expenditures incurred to complete the physical separation of shared locations.

Finally, \$6 million of restructuring and short-term incentive program payments to former senior leadership were reflected in Separation-related transaction costs and other payments for the six month period ended June 30, 2026. These payments were reflected in other cash payments as they related to the establishment of the post-spin leadership structure.

Selected Financial Information and Non-GAAP Measures

DuPont de Nemours, Inc.

Selected Financial Information and Non-GAAP Measures

Net Sales

<i>In millions</i>	2Q26	2Q25
Net Sales	\$ 1,819	\$ 1,749

Non-GAAP Calculation of Operating EBITDA (Unaudited)

<i>In millions</i>	2Q26	2Q25
Income from continuing operations, net of tax (GAAP)	\$ 191	\$ 24
+ Provision for income taxes on continuing operations	75	54
Income from continuing operations before income taxes	\$ 266	\$ 78
+ Depreciation and amortization	154	166
- Interest income ¹	24	18
+ Interest expense	41	84
- Non-operating pension/OPEB benefit costs	(1)	—
- Foreign exchange gains (losses), net	4	(14)
+ Future reimbursable indirect costs	—	25
+ Corporate DDOB Remediation Costs	6	2
- Adjustments for significant items charge	(8)	(72)
Operating EBITDA (non-GAAP)	\$ 448	\$ 423

1. Excludes accrued interest income earned on employee retention credits and employee retention credits and interest income earned on cash held in escrow associated with the Qnity financing.

GAAP Income from Continuing Operations Margin

<i>In millions</i>	2Q26	2Q25
Income from continuing operations margin	10.5%	1.4%

Operating EBITDA Margin

<i>In millions</i>	2Q26	2Q25
Total operating EBITDA margin (non-GAAP) ¹	24.6%	24.2%

1. Operating EBITDA Margin is Operating EBITDA as a percentage of net sales.

Selected Financial Information and Non-GAAP Measures

DuPont de Nemours, Inc.

Adjusted EPS

Pretax Non-GAAP Adjustments to Net Income (Unaudited)

<i>In millions</i>	2Q26	2Q25
Income from continuing operations before income taxes (GAAP)	\$ 266	\$ 78
Less: Significant items charge, before tax ¹	(8)	(72)
Less: Amortization of intangibles, before tax ¹	(68)	(74)
Less: Non-op pension / OPEB benefit costs, before tax ¹	(1)	—
Less: Future reimbursable indirect costs, before tax ¹	—	(25)
Less: Corporate DDOB Remediation Costs, before tax ¹	(6)	(2)
Adjusted earnings, before tax (non-GAAP)	\$ 349	\$ 251

1. Impact on income (loss) from continuing operations before income taxes.

Non-GAAP Adjustments to Net Income (Unaudited)

<i>In millions</i>	2Q26	2Q25
Adjusted earnings, net of tax (non-GAAP)	\$ 257	\$ 177

Non-GAAP Adjustments to Net Income (Unaudited)

<i>In millions</i>	2Q26	2Q25
Adjusted earnings per common share from continuing operations - diluted (non-GAAP)	\$ 1.88	\$ 1.27

Selected Financial Information and Non-GAAP Measures

DuPont de Nemours, Inc. Segment Information (Unaudited)

Net Trade Revenue by Segment and Business or Major Product Line

<i>In millions</i>	2Q26	2Q25
Healthcare Technologies	\$ 473	\$ 444
Water Technologies	383	373
Healthcare & Water Technologies	\$ 856	\$ 817
Industrial Technologies	\$ 538	\$ 513
Building Technologies	425	419
Diversified Industrials	\$ 963	\$ 932
Total	\$ 1,819	\$ 1,749

<i>Percent change from prior year (Unaudited)</i>	<i>Three Months Ended June 30, 2026</i>			
	<i>Organic Sales</i>	<i>Currency</i>	<i>Portfolio / Other</i>	<i>Total</i>
Healthcare & Water Technologies	4 %	1 %	— %	5 %
Diversified Industrials	3	—	—	3
Total	4 %	— %	— %	4 %

Selected Financial Information and Non-GAAP Measures

DuPont de Nemours, Inc. *Segment Information (Unaudited)*

Operating EBITDA

<i>In millions</i>	2Q26	2Q25
Healthcare & Water Technologies	\$ 258	\$ 248
Diversified Industrials	213	199
Corporate	(23)	(24)
Total operating EBITDA (non-GAAP)	\$ 448	\$ 423

Operating EBITDA Margin

<i>In millions</i>	2Q26	2Q25
Healthcare & Water Technologies	30.1 %	30.4 %
Diversified Industrials	22.1 %	21.4 %
Total operating EBITDA margin (non-GAAP) ^{1, 2}	24.6 %	24.2 %

Significant Items (Pretax)

<i>In millions</i>	2Q26	2Q25
Healthcare & Water Technologies	\$ 1	\$ 7
Diversified Industrials	(5)	(2)
Corporate	(4)	(77)
Total significant items charge by segment (Pretax)	\$ (8)	\$ (72)

Depreciation and Amortization (Pretax)

<i>In millions</i>	2Q26	2Q25
Healthcare & Water Technologies	\$ 89	\$ 93
Diversified Industrials	65	62
Corporate	—	11
Total depreciation and amortization by segment (Pretax)	\$ 154	\$ 166

1. Operating EBITDA Margin is Operating EBITDA as a percentage of net sales.

2. Operating EBITDA Margin %'s for Corporate are not presented separately above as they are not meaningful; however, the results of Corporate are included in the total operating EBITDA margin %'s above.



Selected Financial Information and Non-GAAP Measures

DuPont de Nemours, Inc.

Adjusted Free Cash Flow Information (Unaudited)

Reconciliation of "Cash provided by operating activities - continuing operations" to Adjusted Free Cash Flow, Transaction-Adjusted Free Cash Flow and calculation of "Adjusted Free Cash Flow Conversion" and "Transaction-Adjusted Free Cash Flow Conversion" (Unaudited)

<i>In millions</i>	2Q26	2Q25
Cash provided by operating activities (GAAP) - continuing operations	\$ 400	\$ 74
Capital expenditures	(76)	(50)
Adjusted free cash flow (non-GAAP) ¹	\$ 324	\$ 24
Separation-related transaction cost and other payments ²	2	83
Transaction-adjusted free cash flow (non-GAAP) ¹	\$ 326	\$ 107
Adjusted earnings (non-GAAP)	\$ 257	\$ 177
Adjusted free cash flow conversion (non-GAAP) ³	126 %	14 %
Transaction-adjusted free cash flow conversion (non-GAAP) ³	127 %	60 %

1. Calculated on a continuing operations basis for all periods presented.

2. Other payments for the three months ended June 30, 2026 includes \$2 million of separation-related capital expenditures (as defined in our Non-GAAP definitions).

3. Refer to the definitions in the non-GAAP financial measures section for further information.

Selected Financial Information and Non-GAAP Measures

DuPont de Nemours, Inc. Investor Day Basis 2025 Pro Forma

Selected Non-GAAP Calculation of Pro Forma Operating EBITDA (Unaudited)

<i>In millions</i>	FY 2025	4Q25	3Q25	2Q25	1Q25
Income (loss) from continuing operations, net of tax (GAAP)	\$ 98	\$ (108)	\$ 102	\$ 24	\$ 80
+ Provision for (benefit from) income taxes on continuing operations	102	42	(11)	54	17
Income from continuing operations before income taxes	\$ 200	\$ (66)	\$ 91	\$ 78	\$ 97
+ Depreciation and amortization	647	159	162	166	160
- Interest income ¹	72	20	17	18	17
+ Interest expense ²	311	61	84	84	82
- Non-operating pension/OPEB benefit credits	5	3	—	—	2
- Foreign exchange losses, net	(34)	(5)	(12)	(14)	(3)
+ Future reimbursable indirect costs	89	14	25	25	25
+ Corporate DDOB Remediation Costs	12	4	3	2	3
- Adjustments for significant items charge	(412)	(255)	(76)	(72)	(9)
Operating EBITDA (non-GAAP)	\$ 1,628	\$ 409	\$ 436	\$ 423	\$ 360
+ Benefit (hurt) from post-separation Corporate costs ³	19	12	(2)	(7)	16
Pro Forma Operating EBITDA (non-GAAP)	\$ 1,647	\$ 421	\$ 434	\$ 416	\$ 376

1. Excludes accrued interest income earned on employee retention credits and employee retention credits and interest income earned on cash held in escrow associated with the Qnity financing

2. Excludes interest rate swap basis amortization.

3. Amount reflects the impact of post-separation corporate costs and Delrin equity earnings/losses. The pro forma adjustments reflect 2025 costs as if the separation occurred on January 1, 2025 for comparability. The pro forma impact of corporate costs is calculated as the prior year corporate costs (\$144 million) less the pro forma costs (\$125 million from Investor Day), inclusive of the impact of Delrin equity earnings/losses. The \$125 million of pro forma corporate costs were attributed to each quarter equally for purposes of the pro forma calculation.

Pro Forma Operating EBITDA Margin

<i>In millions</i>	FY 2025	4Q25	3Q25	2Q25	1Q25
Total Pro Forma Operating EBITDA Margin (non-GAAP) ¹	24.0%	24.9%	24.2%	23.8%	23.3%

1. Pro Forma Operating EBITDA Margin is Pro Forma Operating EBITDA as a percentage of net sales.

Selected Financial Information and Non-GAAP Measures

DuPont de Nemours, Inc.

Investor Day Basis Pro Forma Adjusted EPS

Pretax Non-GAAP Adjustments to Net Income (Unaudited) - Reflects the impact on income (loss) from continuing operations before income taxes.

<i>In millions</i>	FY 2025	4Q25	3Q25	2Q25	1Q25
Income (loss) from continuing operations before income taxes (GAAP)	\$ 200	\$ (66)	\$ 91	\$ 78	\$ 97
Less: Significant items charge, before tax ¹	(412)	(255)	(76)	(72)	(9)
Less: Amortization of intangibles, before tax ¹	(291)	(71)	(71)	(74)	(75)
Less: Non-op pension / OPEB benefit credits, before tax ¹	5	3	—	—	2
Less: Future reimbursable indirect costs, before tax ¹	(89)	(14)	(25)	(25)	(25)
Less: Corporate DDOB Remediation Costs, before tax ¹	(12)	(4)	(3)	(2)	(3)
Adjusted earnings, before tax (non-GAAP)	\$ 999	\$ 275	\$ 266	\$ 251	\$ 207
Plus: Interest expense benefit from post-separation capital structure, before tax ¹	129	14	39	39	37
Plus: Benefit from rightsizing of Corporate costs, before tax ¹	19	12	(2)	(7)	16
Pro Forma Adjusted earnings, before tax (non-GAAP)	\$ 1,147	\$ 301	\$ 303	\$ 283	\$ 260

Non-GAAP Adjustments to Earnings Per Share (Unaudited) - Earnings (loss) per share amounts from continuing operations - diluted for the year may not equal the sum of the quarterly earnings (loss) per common share from continuing operations - diluted amounts due to the change in average share calculations.

<i>In millions</i>	FY 2025	4Q25	3Q25	2Q25	1Q25
Earnings (loss) per common share from continuing operations - diluted (GAAP)	\$ 0.63	\$ (0.81)	\$ 0.70	\$ 0.17	\$ 0.56
Less: Significant items (charge) benefit - diluted	(2.26)	(1.72)	(0.04)	(0.54)	0.02
Less: Amortization of intangibles - diluted	(1.62)	(0.39)	(0.39)	(0.41)	(0.42)
Less: Non-op pension / OPEB benefit credits - diluted	0.03	0.02	—	—	0.01
Less: Future reimbursable indirect costs - diluted	(0.50)	(0.08)	(0.14)	(0.15)	(0.14)
Less: Corporate DDOB Remediation Costs - diluted	(0.06)	(0.03)	(0.02)	—	(0.01)
Adjusted earnings per common share from continuing operations - diluted (non-GAAP)	\$ 5.04	\$ 1.39	\$ 1.29	\$ 1.27	\$ 1.10
Plus: Interest, net benefit from post-separation capital structure ¹	0.65	0.07	0.19	0.19	0.20
Plus: Benefit (hurt) from rightsizing of Corporate costs ²	0.09	0.06	(0.01)	(0.04)	0.08
Less: Impact of tax rate change ³	0.37	0.11	0.12	0.14	(0.01)
Pro Forma Adjusted earnings per common share from continuing operations - diluted (non-GAAP)	\$ 6.15	\$ 1.63	\$ 1.59	\$ 1.56	\$ 1.37

1. The interest benefit reflects the impact of DuPont's post-separation capital structure as if the separation occurred on January 1, 2025 for comparability. The full year 2025 pro forma net interest impact represents the prior year interest expense of \$239 million less pro forma net interest expense of \$110 million. The benefit excludes the interest income expected from the Aramids Divestiture.

2. The Corporate cost benefit relates to the impact of post-separation corporate costs and Delrin equity earnings/losses. The pro forma adjustments reflect 2025 costs as if the separation occurred on January 1, 2025 for comparability. The pro forma impact of corporate costs is calculated as the prior year corporate costs (\$144 million) less the pro forma costs (\$125 million from Investor Day), inclusive of the impact of Delrin equity earnings/losses. The \$125 million of pro forma corporate costs were attributed to each quarter equally for purposes of the pro forma calculation.

3. The pro forma adjustment is tax effected using the expected base tax rate less the expected base tax rate in 2026 (25.5%).



